XGN News and Press, Exagen Inc.

2024-05-13 11:25:02 ET Exagen, Inc. (XGN) Q1 2024 Earnings Conference Call May 13, 2024 08:30 AM ET Company Participants Ryan Douglas - Investor Relations John Aballi - President and Chief Executive Officer Kamal Adawi - Chief Financial Officer Conference C...

2024-05-13 08:03:30 ET More on Exagen Seeking Alpha’s Quant Rating on Exagen Historical earnings data for Exagen Financial information for Exagen Read the full article on Seeking Alpha For further details see: Exagen beats top-line and bott...

CARLSBAD, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2024. First Quarter Highlights: Recognized total revenue of $14.4 million in the ...

Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...

CARLSBAD, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2024, before the market opens on Monday, May 13, 2024. John Aballi, Exagen’s President and Chief Executiv...

CARLSBAD, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced changes to the Board of Directors. Exagen is pleased to announce Scott Kahn, Ph.D. is joining the Board as a Class I Director. Dr. Kahn has a d...

2024-03-18 13:23:06 ET Exagen Inc. (XGN) Q4 2023 Earnings Conference Call March 18, 2024, 8:30 a.m. ET Company Participants John Aballi - President and CEO Kamal Adawi - CFO Ryan Douglas - IR Conference Call Participants Mark Massaro - BTIG Kyle M...

2024-03-18 11:27:21 ET More on Exagen Exagen reaffirms FY23 revenue of at least $50M Seeking Alpha’s Quant Rating on Exagen Historical earnings data for Exagen Financial information for Exagen Read the full article on Seeking Alpha For ...

2024-03-18 10:00:18 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Johnson & Johnson, Boston...

CARLSBAD, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year ended December 31, 2023. Financial Highlights: Record total revenue of $52...